WO2023181076 - PROCESS FOR PREPARATION OF PURE SITAGLIPTIN AND SALTS THEREOF
National phase entry is expected:
Publication Number
WO/2023/181076
Publication Date
28.09.2023
International Application No.
PCT/IN2023/050283
International Filing Date
24.03.2023
Title **
[English]
PROCESS FOR PREPARATION OF PURE SITAGLIPTIN AND SALTS THEREOF
[French]
PROCÉDÉ DE PRÉPARATION DE SITAGLIPTINE PURE ET DE SES SELS
Applicants **
DR. REDDY'S LABORATORIES LIMITED
House No. 8-2-337
Street Road No. 3, Banjara Hills
Hyderabad, Telangana 500034, IN
Inventors
KURELLA, Srinivas
House No. 2-66/5, Plot No.5, Gajularamaram, Qutubullapur, Hyderabad, Telangana.
Hyderabad 500055, IN
PANUGANTI, Ranjeeth
House No. 16-117/596, Plot No. 596, Alwyn colony, Patancheru, Hyderabad, Telangana.
Hyderabad 502319, IN
Priority Data
202241016929
25.03.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1512 | |
| EPO | Filing, Examination | 11420 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 13035 |
Total: 27136 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application relates to substantially pure Sitagliptin and its pharmaceutically acceptable salts, and more particularly a process for preparing substantially pure Sitagliptin and its pharmaceutically acceptable salts and pharmaceutical compositions thereof. The present application also describes pharmaceutical compositions comprising sitagliptin or a salt thereof having less than about 100 ppm of compound of formula VII and/or less than about 1 ppm of Nitrosamine impurity of the compound of formula VIII.[French]
La présente demande concerne de la sitagliptine sensiblement pure et ses sels pharmaceutiquement acceptables, et plus particulièrement un procédé de préparation de sitagliptine sensiblement pure et de ses sels pharmaceutiquement acceptables et des compositions pharmaceutiques associées. La présente demande concerne également des compositions pharmaceutiques comprenant de la sitagliptine ou un sel de celle-ci ayant moins d'environ 100 ppm de composé de formule VII et/ou moins d'environ 1 ppm d'impureté nitrosamine du composé de formule VIII.